Arriving in the arena of obesity therapy, retatrutide is a distinct strategy. Unlike many existing medications, retatrutide functions as a dual agonist, concurrently targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. The concurrent engagement fosters several helpful effects, like improved